Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FDMT vs EDIT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EDIT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 3–5 Matrix Metrics)

EDIT Overall Winner 6-Pillar Tally: FDMT 1 – 5 EDIT Matrix Metrics: FDMT 5 – 3 EDIT

As of Nov 16, 2026, Editas Medicine, Inc. (EDIT) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). FDMT carries a Unified Composite Score of 42.1/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin), whereas EDIT carries 51.6/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin).

  • Growth vs. Quality Trade-Off: EDIT earns the overall head-to-head edge with a stronger Unified Composite Score (51.6/100 HOLD vs. FDMT 42.1/100 HOLD) and 2.32β · 102% Vol risk profile, whereas FDMT leads top-line expansion (+4505.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FDMT vs EDIT
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.89β · 90% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 21.0 Fund 54.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $12.12 · SMA50: $13.08
EDIT NASDAQ Head-to-Head Winner
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 35
RSI-14: 35.1 · SMA20: $2.52 · SMA50: $2.61

6-Pillar Scorecard Institutional Category Breakdown (FDMT 1 – 5 EDIT)

Columns: Metric · FDMT · EDIT
1. Valuation Multiples EDIT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 6.6x 5.2x
2. Growth & Scale FDMT
Revenue Growth (YoY) +4505.6% +37.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $96M $50M
Market Cap $669.3M $336.5M
3. Profitability & Quality EDIT
Gross Margin N/A -73.3%
Operating Margin -222.7% -167.0%
Net Profit Margin -208.6% -144.9%
Return on Equity (ROE) -56.7% -147.4%
4. Balance Sheet & Cash Flow EDIT
Cash Generation (TTM) -$156M -$110M
Cash Flow Margin N/A N/A
Net Cash / Leverage $31M Net Cash $79M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EDIT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 82.4% (10th %ile) 95.8% (38th %ile)
Put/Call OI Skew 5.16x (Put-Skewed) 0.29x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat EDIT
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Concentrated Oligopoly Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FDMT (5) vs EDIT (3)
Institutional Metric FDMT EDIT Criterion Row Edge
Market Capitalization
Scale
$669.3M $336.5M Larger Scale FDMT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+4505.6% +37.4% Higher Growth FDMT
Operating Margin (TTM)
Profitability
-222.7% -167.0% Higher Margin EDIT
Net Profit Margin
Profitability
-208.6% -144.9% Higher Margin EDIT
Return on Equity (ROE)
Capital Efficiency
-56.7% -147.4% Higher ROE FDMT
52-Week Range Position
Momentum
47% ($7–$17) 11% ($2–$4) Stronger Trend FDMT
Beta / 30D Volatility
Risk Regime
1.89β · 90% Vol 2.32β · 102% Vol Lower Realized Risk FDMT
Unified Institutional Score
Composite Signal
42.1 / 100 (HOLD) 51.6 / 100 (HOLD) Higher Composite EDIT
Trailing 12M Revenue (USD)
Operating Scale
$96M $50M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -73.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.6x EV/Rev N/M PEG · 5.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$156M ($31M Net Cash) -$110M ($79M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FDMT +14.9 pp
FDMT: -4.04% · EDIT: -18.94%
3M Horizon FDMT +12.99 pp
FDMT: -20.86% · EDIT: -33.85%
6M Horizon FDMT +63.97 pp
FDMT: +39.27% · EDIT: -24.7%
1Y Horizon FDMT +38.33 pp
FDMT: +13.33% · EDIT: -25.0%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FDMT Revenue EDIT Revenue FDMT Op. Margin EDIT Op. Margin Margin Leader
FY2018 N/A $30M N/A -356.1% EDIT
FY2019 $10M $20M -729.4% -686.4% EDIT
FY2020 $10M $90M -424.0% -148.6% EDIT
FY2021 $20M $30M -395.5% -756.1% FDMT
FY2022 $0M $20M -3516.5% -1146.3% EDIT
FY2023 $20M $80M -544.6% -216.6% EDIT
FY2024 $0M $30M -507678.4% -777.2% EDIT
FY2025 $90M $40M -187.2% -394.9% FDMT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing

Investor FAQ FDMT vs EDIT Key Questions & Quantitative Answers

As of Nov 16, 2026, Editas Medicine, Inc. (EDIT) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). FDMT carries a Unified Composite Score of 42.1/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin), whereas EDIT carries 51.6/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin). Growth vs. Quality Trade-Off: EDIT earns the overall head-to-head edge with a stronger Unified Composite Score (51.6/100 HOLD vs. FDMT 42.1/100 HOLD) and 2.32β · 102% Vol risk profile, whereas FDMT leads top-line expansion (+4505.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with EDIT at +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FDMT cumulative revenue shifted +800.0% while EDIT shifted +33.3%. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EDIT.

EDIT screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus EDIT (-147.4% ROE) capital efficiency.

In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk). By comparison, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.